Docetaxel (Tautax) in the treatment of hormone-refractory prostate cancer

I. G. Rusakov, B. V. Buharkin, A. M. Ataev, G. V. Vereshagin
2020 Onkourologiâ  
Purpose. Evaluate efficacy and portability of the combination of the drugs Tautax (docetaxel) with a dose of 75mg/m2 1 time per 21 days and prednisolone — 10 mg per 24 h in hormone-refractory prostate cancer (HRPC) patients. Methods. Patients with verified HRPC were included in the study. Patients without being performed orchofuniculectomy were given LHRH analogues during the entire study. The treatment scheme was: tautax 75 mg/m2 1 time per 21 days as 1,5 h infusion + prednisolone — 10 mg per
more » ... 4 h per os. Dexamethasone 8 mg was introduced intramuscularly as a premedication before tautax infusion prior to 12, 6 and 1 h. Patients with the revealed bone metastases were given zoledronic acid 4 mg 1 time per 28 days. The therapy was has been being performed for 6 months or till disease progression revelation. In case of regression or stabilization of the disease, up to 10 chemotherapy courses were performed. Results. 29 HRPC patients are examined. 178 chemotherapy courses are performed. Partial regression is noted in 8 (28%) patients, stabilization — in 9 (31%), progression - in 8 (28%) patients. PSA level decrease >50% has been observed in 19 (65,5%) patients. Improvement of the life quality was reached in 11 (38%) patients. The decrease in hyperfixation of radiopharmaceutical by osteoscintigraphy ocurred in 14 (48%) patients. Conclusion. Combination of Tautax and prednisolone is an effective treatment regimen of the HRPC patients.
doi:10.17650/1726-9776-2008-4-2-62-67 doaj:8da6804cbbbc4630bd1b6ce297ee30d4 fatcat:tst7i36yvzdrlfi236qhrmylwe